News

Currie Medical to expand in Norfolk

Currie Medical, a medical device manufacturer, plans to invest $1.22 million to expand its operations in Norfolk, creating an estimated 60 jobs.

Based in Franklin, Tennessee, Currie Medical will lease a 30,000-square-foot building at 3701 E. Virginia Beach Blvd. in Norfolk, where it will house its medical device reprocessing operation and distribution center. Currie has 15 employees in Norfolk and employs about 45 people total between Virginia and Tennessee, according to co-owner Carter Smith. The new facility is expected to be in full operation and fully staffed in the first quarter of 2025, he added.

“Currie Medical is excited to expand our operations into the vibrant business community of Norfolk,” Smith and co-owner Owen Griffin said in a statement. “This region offers us a skilled workforce, strong infrastructure and a supportive environment that fosters growth and innovation in the medical technology sector. With this investment, we are committed to bringing new job opportunities to the area and continuing to develop new solutions in medical device reprocessing. We look forward to contributing to the advancement of health care with our growing Norfolk-based team.”

The Virginia Economic Development Partnership worked with the City of Norfolk and the Hampton Roads Economic Development Alliance to secure the project, and the Virginia Jobs Investment Program will assist Currie Medical with consultation and funding for recruitment and training activities. The company is also eligible for state benefits through the Port of Virginia Economic and Infrastructure Development Zone Grant Program.

“Currie Medical’s expansion in Norfolk highlights Virginia’s growing prowess in specialized manufacturing,” Gov. Glenn Youngkin said in a statement. “This project not only adds to our skilled workforce but also strengthens our reputation as a hub for innovative medical technology solutions. We are proud to have them in the commonwealth for years to come.”

Read more here.

Recent News

03/31/2025

Allozymes and Bonumose Collaborate to Accelerate Enzyme Innovations for Beneficial Food & Supplement Ingredients

Allozymes, a leader in protein engineering, and Bonumose, a leader in innovative enzyme combinations enabling the production of high-volume, healthy, naturally occurring monosaccharides from commodity feedstocks such as starch and sugar, announce the preliminary results of improvements to key enzymes for Bonumose’s ingredient production process. Bonumose enzyme breakthroughs include unique combinations converting plant-based starch and

03/26/2025

New survey: U.S. biotechs warn tariffs could impede access to cures, stifle innovation

Today, the Biotechnology Innovation Organization (BIO) released results from a membership survey that underscores the significant, global integration of the biomedical supply chain. According to the findings, nearly 90% of U.S. biotech companies rely on imported components for at least half of their FDA-approved products — making the supply of medicines for US patients and

03/25/2025

AgroSpheres Named on Both the World’s Top GreenTech Companies 2025 and America’s Top GreenTech Companies 2025 Lists by TIME Magazine

AgroSpheres has been named on both the World’s Top GreenTech Companies 2025 and America’s Top GreenTech Companies 2025 lists. These prestigious awards are presented by TIME and Statista Inc., the leading statistics portal and industry ranking provider. The award lists were announced on March 25th, 2025, and can be viewed on TIME’s website. Statista ranked